Overview

* CorMedix Q2 2025 rev of $39.7 mln beats analyst expectations, per LSEG data

* EPS for Q2 2025 beats consensus, driven by DefenCath sales, per LSEG data

* Co announces acquisition of Melinta Therapeutics, closing expected by Sept 1, 2025

Outlook

* Company expects sufficient resources to fund operations for at least 12 months

* CorMedix ( CRMD ) anticipates closing Melinta acquisition by September 1, 2025

Result Drivers

* DEFENCATH SALES - Significant increase in DefenCath sales drove Q2 2025 revenue growth, per company

* OPERATING EXPENSES - Rise in operating expenses due to increased G&A and R&D costs, per company

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $39.70 $34 mln

Revenue mln (7

Analysts

)

Q2 EPS Beat $0.28 $0.17 (7

Analysts

)

Q2 Net Beat $19.80 $12 mln

Income mln (6

Analysts

)

Q2 Basic $0.29

EPS

Q2 $18.30

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy"

* Wall Street's median 12-month price target for CorMedix Inc ( CRMD ) is $20.00, about 40.3% above its August 6 closing price of $11.95

* The stock recently traded at 8 times the next 12-month earnings vs. a P/E of 10 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)